Home > Inhibitors & Agonists > Cell Cycle/DNA Damage > Monopolar Spindle 1 (Mps1/TTK)
Cat. No. Product name CAS No.
DC11704 CFI-401870

A potent, selective, orally active Mps1 (TTK) inhibitor with IC50 of 3.1 nM.

DC11677 CCT-271850

A potent, selective, orally bioavailable Mps1 kinase inhibitor with IC50 of 11 nM.

DC7072 AZ3146 Featured

AZ3146 is a potent and selective monopolar spindle 1 (Mps1) kinase inhibitor (IC50 = 35 nM); less potent to FAK, JNK1, JNK2, and Kit.

DC9679 BAY1217389 Featured

BAY1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity.

DC7470 MPI-0479605 Featured

MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 with IC50 of 1.8 nM, >40-fold selectivity over other kinases.

DC8119 Mps1-IN-2 Featured

Mps1-IN-2 is a potent Mps1 kianse inhibitor with IC50 value of 145 nM.

DC5087 Mps1-IN-1

Mps1-IN-1 is a highly potent and selectibe Mpsl inhibitor with IC50 of 367 nM; >1000-fold selectivity relative to the 352 member kinase panel with the major exceptions of Alk and Ltk.

DC7866 NMS-P715 Featured

NMS-P715 is the first selective, ATP-competitive and orally bioavailable MPS1 small-molecule inhibitor(IC50=8 nM); selectively reduces cancer cell proliferation, leaving normal cells almost unaffected.

DC28264 TC-Mps1-12

TC-Mps1-12 is a potent and selective monopolar spindle 1 (Mps1) inhibitor, with an IC50 of 6.4 nM.

DC50255 RMS-07

RMS-07 is a covalent Monopolar Spindle Kinase 1 (MPS1/TTK) inhibitor, with an apparent IC50 of 13.1 nM. RMS-07 targets a poorly conserved cysteine in the kinase's hinge region.

DC70063 CFI-402257

A potent and selective Mps1/TTK kinase inhibitor with Ki of 0.1 nM and cellular Mps1 EC50 of 6.5 nM.

DC70740 RMS-07

RMS-07 (RMS 07) is the first potent, selective irreversible covalent inhibitor of Monopolar spindle kinase 1 (MPS1/TTK) with IC50 of 13 nM, Ki of 0.83 nM; demonstrated intracellular target engagement with IC50 of 22.4 nM, shows a high selectivity against MAPKAPK2/3, FGFR4, p70S6Kβ (IC50>1 uM); RMS-07 induced cell cycle arrest with a prolonged G2/M phase, downregulated cyclin B1, whereas it upregulated p53, p21, and phospho-γH2A.X, enhanced cleaved PARP levels; RMS-07 attenuates cancer cell proliferation, RMS-07 and Navitoclax synergistically inhibit hepatocellular carcinoma cell proliferation.

Page 1 / Total 1 FirstPrevNextLastGoto